XENE
Xenon Pharmaceuticals Inc.43.00
-0.60-1.38%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
3.32BP/E (TTM)
-Basic EPS (TTM)
-3.89Dividend Yield
0%Recent Filings
8-K
Positive X-TOLE2 topline data
Xenon announced positive Phase 3 X-TOLE2 topline data on March 9, 2026, showing azetukalner slashed monthly focal onset seizures by -53.2% at 25 mg versus -10.4% placebo (p=0.000000000006), with 54.8% responders versus 20.8%. Safety matched prior studies; NDA submission planned for Q3 2026. Data beats Phase 2b. Forward-looking risks apply.
8-K
New $400M ATM registration
Xenon Pharmaceuticals filed a prospectus supplement on February 27, 2026, registering $400 million of common shares under its existing at-the-market sales agreement with Jefferies and Stifel. It supersedes the prior prospectus, terminating that offering after selling $291 million in shares. Fresh capacity bolsters funding flexibility. No sales terms disclosed.
8-K
Q4 2025 results; X-TOLE2 soon
Xenon Pharmaceuticals reported full-year 2025 net loss of $345.9 million, up from $234.3 million in 2024, driven by $300.9 million R&D spend on azetukalner Phase 3 trials. Pro forma cash hit $716 million post-ATM raises, funding ops into H2 2027. X-TOLE2 topline drops first half March 2026. Clinical risks loom large.
10-K
FY2025 results
Xenon Pharmaceuticals posted FY2025 net losses of $345.9M, up from $234.3M in FY2024, driven by ramped R&D spend to $300.9M (from $210.4M) as Phase 3 trials for azetukalner in epilepsy, MDD, and BPD enrollment accelerated; Q4 expenses surged on clinical momentum, with direct azetukalner costs hitting $166M annually. Cash burned $279M operationally but closed at $586M after $112M ATM equity raise, funding ops into 2027. No revenue beyond a $7.5M Neurocrine milestone. X-TOLE2 topline due H1 2026. Clinical trial delays could stall pipeline momentum.
8-K
Inducement plan shares up 125K
Xenon Pharmaceuticals amended its 2025 Inducement Equity Incentive Plan on November 24, 2025, boosting the share reserve from 775,000 to 900,000 common shares. This bolsters hiring firepower for new employees via stock options, RSUs, and performance awards—Nasdaq-compliant, no shareholder vote needed. Capacity expanded. Inducements fuel talent grabs.
ALZN
Alzamend Neuro, Inc.
2.16+0.05
DRUG
Bright Minds Biosciences Inc.
93.99+8.32
NBIX
Neurocrine Biosciences, Inc.
148.74-5.32
NGNE
Neurogene Inc.
19.53-0.73
NMRA
Neumora Therapeutics, Inc.
1.85-0.11
NRSN
NeuroSense Therapeutics Ltd.
0.85+0.01
NRXP
NRX Pharmaceuticals, Inc.
2.10+0.12
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
XBIO
Xenetic Biosciences, Inc.
2.07-0.27
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05